Pharmacia & Upjohn Ab

Consejo Superior De Investigaciones Cientificas

Esperion Therapeutics, Inc.

Pharmacia & Upjohn Aktiebolag

Pharmacia Aktiebolag

Peter Lind

Cesare Sirtori

Erik Holmgren

Mats Lake

Joanna Chmielewska

Guido Franceschini

Lars B Abrahmsen

Jan Holmgren

Bj&ouml;rn M Nilsson

Carlos Martinez Alonso

Bjorn Nilsson

Jose Mario Garcia

Jose Miguel Frade

Erik Walum

Lars Abrahms&eacute;n

Leif G Lindholm

Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.

Dimer of molecular variant of apolipoprotein and processes for the production thereof

The invention relates to antibodies which is capable of binding the monocyte chemoattractant protein 1 (MCP-1) receptor CCR2, especially those which are capable of acting either as an antagonist or agonist. The claimed antobodies can be used for in vitro and/or in vivo diagnostic, for screening and detection of tissues and classes of cells expressing the MCP-1 receptor, for screening for new drugs and for therapeutic use. The invention also relates to a preparation comprising the claimed antibody and a micro-organism or cell-line capable of producing the claimed antibody.

Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)

The invention relates to a method for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus by administering a drug capable of modulating the regulation of UCP-2, the use of a drug capable of modulating the regulation of UCP-2 for the production of drug for treatment of obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and pharmaceutical composition comprising a pharmaceutically effective amount of such a drug. The invention is also related to methods for screening for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus and the use of cDNA probe for determination of upregulation of UCP-2 for potential drugs against obesity, metabolic syndrome and/or non-insulin dependent diabetes mellitus.

Methods of screening for modulators of uncoupling protein-2 (UCP-2) as

Dimer of molecular variant of apolipoprotein and processes for the

A monoclonal antibody that reacts with the CA-242 antigen is provided. The antibody can be obtained by culturing the hybridoma cell line C242:II with the ECACC identification number 90012601, or an artificial or spontaneous mutant thereof. Cell lines producing the antibody are also provided. The antibody is useful for therapeutic and diagnostic purposes.

Tumor antigen specific antibody

Growing community of inventors

Uppsala, Sweden

Peter Lind